Problems with K-Y Liquibeads, O.B. Tampons Not Investigated: FDA Warns

Johnson & Johnson’s McNeil unit has received a warning letter from the FDA for failing to properly respond to consumer complaints about problems with K-Y Liquibeads vaginal moisturizer, O.B. Tampons and other products. 

The FDA warning letter arose from a December inspection of the company’s Skillman, New Jersey facility and comes only a year after Johnson & Johnson was forced to sign a consent decree where it promised that it would tackle quality control issues.

Most of the warning letter is focused on K-Y brand LiquiBeads Vaginal Moisturizer, indicating that McNeil failed to properly respond to nearly 70 complaints about the LiquiBeads, many of which mentioned problems getting the beads to dissolve or providing inconsistent lubrication. The company received 227 complaints involving problems with the vaginal moisturizer beads from June 25, 2010 through December 12, 2011.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Some cases where the beads reportedly did not dissolve properly or reportedly had uncharacteristic texture were closed by the manufacturer without any written justification, the FDA inspectors found. In some cases, the company reported that the lot numbers on the complaints were invalid and dismissed them, but FDA inspectors found that they were indeed valid numbers.

In addition to the complaints, the FDA says the company botched long-term stability studies for the LiquiBeads and did not properly test their compatibility with latex condoms.

The company also had problems responding to other complaints as well. Information about a patient diagnosed with toxic shock syndrome after using an O.B. tampon and another complaint involving a consumer who lost a tooth while using Reach dental floss were both submitted to the FDA later than regulations allow. The FDA says that since the inspection the company’s response to the delayed complaint submissions appears to be adequate.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025
Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025 (Posted today)

A series of four bellwether claims in the baby formula NEC lawsuit MDL will be ready to go before a federal juries in May 2025, August 2025, November 2025 and February 2026 according to a proposed trial schedule agreed upon by both plaintiffs and defendants.

AngioDynamics Port Catheter Lawsuit MDL Established in Southern District of California
AngioDynamics Port Catheter Lawsuit MDL Established in Southern District of California (Posted yesterday)

U.S. JPML has transferred all AngioDynamics port catheter lawsuits to the U.S. District Court for the Southern District of California, for coordinated discovery and pretrial proceedings as part of a federal MDL (multidistrict litigation).